Skip to main content
Premium Trial:

Request an Annual Quote

MolDx Finalizes Expanded Coverage for Liquid Biopsies

NEW YORK – Wisconsin Physicians Service Insurance Corporation released its final coverage policy on Thursday for the Guardant360 liquid biopsy assay.

The policy stipulates that WPSIC will only cover the Guardant360 assay if the patient has a recurrent, relapsed, refractory, metastatic, or advanced solid tumor that didn't originate from the central nervous system. The Medicare contractor further noted that patients who have an NTRK mutation and meet all the indications in the US Food and Drug Administration-approved label for larotrectinib (Bayer's Vitrakvi) can be considered to have advanced cancer. The patient can't have been previously tested with Guardant360 for the same primary cancer, and the patient must have decided to seek further cancer treatment.

If the patient has decided to seek further treatment, the patient has to be a candidate for treatment with a drug that is either approved by the FDA or has a National Comprehensive Cancer Network (NCCN) 1 or NCCN 2A recommendation for the cancer; the FDA-approved indication or NCCN recommendation must require the presence or absence of a genetic biomarker gauged by the Guardant360 assay; and tissue-based comprehensive genomic profiling must not be feasible.

Other liquid biopsies will be covered for the same indications if they display similar performance in their intended use applications to Guardant360. This coverage determination goes into effect March 15.

WPSIC is a member of the MolDx program, and this determination aligns with Palmetto's final coverage determination, which was released in December. The Palmetto decision goes into effect Feb. 3.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.